Skip to content

Cannabis Use and the Risk for Psychosis and Affective Disorders

Lucia Sideli, Harriet Quigley, Caterina la Cascia, R. Murray

Journal of dual diagnosis January 2, 2020 DOI: 10.1080/15504263.2019.1674991 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review Cross-sectional Peer reviewed
Topics Cannabis
Key findings Heavy use of high-THC/low-CBD cannabis increases the risk of psychosis, with smaller but growing evidence for mania and suicide, but not for depression or anxiety.

Abstract

Abstract

Objective: This review discusses the relationship between cannabis use and psychotic, bipolar, depressive, and anxiety disorders, as well as suicide. It summarizes epidemiological evidence from cross-sectional and long-term prospective studies and considers possible etiological mechanisms.

Methods: Systematic reviews and methodologically robust studies in the field (from inception to February 2019) were identified using a comprehensive search of Medline, PsychINFO, and Embase and summarized using a narrative synthesis.

Results: Consistent evidence, both from observational and experimental studies, has confirmed the important role of cannabis use in the initiation and persistence of psychotic disorders. The size of the effect is related to the extent of cannabis use, with greater risk for early cannabis use and use of high-potency varieties and synthetic cannabinoids. Accumulating evidence suggests that frequent cannabis use also increases the risk for mania as well as for suicide. However, the effect on depression is less clear and findings on anxiety are contradictory with only a few methodologically robust studies. Furthermore, the relationship with common mental disorders may involve reverse causality, as depression and anxiety are reported to lead to greater cannabis consumption in some studies. Pathogenetic mechanisms focus on the effect of tetrahydrocannabinol (THC, the main psychoactive ingredient of cannabis) interacting with genetic predisposition and perhaps other environmental risk factors. Cannabidiol (CBD), the other important ingredient of traditional cannabis, ameliorates the psychotogenic effects of THC but is absent from the high-potency varieties that are increasingly available.

Conclusions: The evidence that heavy use of high-THC/low-CBD types of cannabis increases the risk of psychosis is sufficiently strong to merit public health education. Evidence of similar but smaller effects in mania and suicide is growing, but is not convincing for depression and anxiety. There is much current interest in the possibility that CBD may be therapeutically useful.

Comparable studies

Other systematic reviews and meta-analyses on cannabis, most cited first.

Study Year Design Participants
Effects of cannabis use on outcomes of psychotic disorders: systematic review People with psychotic disorders, as examined in 13 longitudinal studies 2008 Systematic review
The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample Patients with established schizophrenia (meta-analysis: 572) and patients with... 2010 Meta-analysis and cross-sectional observational study n = 700
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review 2020 Systematic review
Neuroimaging in cannabis use: a systematic review of the literature Cannabis users and controls in neuroimaging studies 2009 Systematic review
Human Laboratory Studies on Cannabinoids and Psychosis. Healthy human subjects and individuals with schizophrenia 2016 Systematic review

Citations in the library

Cited by 24

and 19 more in the library

Cites 31

and 26 more in the library

Explore topics